India, Sept. 21 -- Some of the newest cancer drugs work like guided missiles. An antibody finds the tumour and delivers a powerful payload straight to it. Making them is hard, because it means handling highly toxic compounds and joining them precisely to a fragile biological molecule. Few drug companies want to build that capability themselves, so they hand the work to specialist contract manufacturers. Those manufacturers depend heavily on their regulatory inspection records.

Shares of Cohance Lifesciences Ltd. were trading at Rs. 145.94, up 1.06 percent from previous close of Rs. 144.41. The stock opened at Rs. 145.00, reaching an intraday high of Rs. 154.85 and low of Rs. 143.96. The company currently has a market capitalization of Rs...